UBL3 Activators
UBL3, also known as Ubiquitin-Like 3, is a protein encoded by the UBL3 gene in humans. This protein belongs to the ubiquitin-like protein family, which is characterized by its similarity to ubiquitin, a small regulatory protein that has a vital role in ubiquitination, a process that tags proteins for degradation by the proteasome or alters their cellular location and activity.
Unlike ubiquitin, which is primarily associated with protein degradation, UBL3 and other ubiquitin-like proteins are implicated in diverse cellular processes, including protein stabilization, cell cycle regulation, and signal transduction. UBL3 specifically is known to be conjugated to target proteins through a post-translational modification known as lipidation. This modification is essential for membrane targeting and subcellular localization of proteins, which is crucial for their proper function.The functional role of UBL3 is not as extensively studied as ubiquitin, but it is believed to play a role in the modification of membrane proteins and to impact their trafficking and function. For instance, UBL3 has been shown to modify the beta2-adrenergic receptor, a well-known G protein-coupled receptor, which suggests its potential involvement in the regulation of receptor-mediated cellular signaling pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that can affect ubiquitin-proteasome pathways, potentially impacting UBL3-related processes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is another proteasome inhibitor, used to disrupt protein degradation pathways, possibly affecting UBL3 function. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
PYR-41 is a ubiquitin-activating enzyme E1 inhibitor, which could influence ubiquitin-like protein pathways, potentially impacting UBL3. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome, affecting protein degradation and potentially influencing UBL3 function. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide and its derivatives modulate the ubiquitin-proteasome system, potentially affecting UBL3 activity. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN4924 inhibits NEDD8-activating enzyme, affecting neddylation, a process similar to ubiquitination, potentially influencing UBL3. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin can modulate various cellular signaling pathways, potentially influencing ubiquitin-like processes and UBL3 activity. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $127.00 $572.00 $4090.00 $20104.00 | 20 | |
Withaferin A is known to inhibit proteasomal activity, potentially impacting pathways involving UBL3. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine can affect lysosomal degradation, which is interconnected with ubiquitin-proteasome pathways, potentially impacting UBL3. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a kinase involved in cellular growth and stress responses, potentially affecting UBL3 function. | ||||||